1 Current Issues for Conduction of BE Studies in Pakistan 1 st Symposium on Bioequivalence and Bioavailability Studies 15-16 April 2014, Lahore, Pakistan.

Slides:



Advertisements
Similar presentations
The Role of the IRB An Institutional Review Board (IRB) is a review committee established to help protect the rights and welfare of human research subjects.
Advertisements

JFDA & HAI Workshop Towards equitable and affordable medicine prices policy in Jordan 4-5 December 2007 Strategies to aid market entry and competition.
Quality Assurance Processes for TB Drugs. GDF Quality Assurance Processes.
Pharmacy Services Agreements Dimitry Gotlinsky Western University Managed Care Clerkship ProPharma Pharmaceutical Consultants, Inc. 5/08/06.
Adapted from ISEF webpage Society for Science and the Public “Roles and Responsibilities of students and adults” Roles and Responsibilities of students.
 Contracts  Subcontracting  Suppliers  Complaints  Corrective and preventive actions (CAPA)  Internal audits  Management reviews Management requirements.
M N P Onshore & Offshore SHIPBUILDING PROJECTS JSC "KRASNOE SORMOVO" SHIPYARD"
Introduction to PPDs Regulatory requirements and rationale.
GCP compliance for GenISIS  This presentation is intended for clinical staff involved in recruiting patients to the GenISIS (Genetics of Influenza Susceptibility.
Laboratory Personnel Dr/Ehsan Moahmen Rizk.
International Experience in Pharmaceutical Services for Promoting Access to Medicines: Canada, Cuba, England, Mexico International Seminar on the Challenges.
Regulatory Body MODIFIED Day 8 – Lecture 3.
ISO 9000:2000 Quality system standards adopted in 1987 by International Organization for Standardization; revised in 1994 and 2000 Technical specifications.
Kyiv, TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Validation of Analytical Methods Used For Bioequivalence.
Tanzania, August, 2006 Dr. Barbara Sterzik, BfArM, Bonn 1 Guidelines and Tools available TRS 937 and BTIF (Bioequivalence Trial Information Form)
Good Clinical Practice GCP
Pharmacy and Therapeutics Committee
World Health Organization
Federal Institute for Drugs and Medical Devices The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health 1 Quality of Bioequivalence.
Good Laboratory Practice
Assessment of Interchangeable Multisource Medicines Quality of BE Data Dr. Henrike Potthast Training workshop: Assessment of Interchangeable.
International Research & Research Involving Children K. Lynn Cates, MD Assistant Chief Research & Development Officer Office of Research & Development.
A Review of Board of Health Liability James A. LeNoury LeNoury Law Counsel to alPHa February 5th, 2015.
Target Institute of Medical Education & Research (TIMER) Provides Clinical Research services to Pharmaceutical, Biotechnology product companies right.
Organization and Implementation of a National Regulatory Program for the Control of Radiation Sources Staffing and Training.
Pre-Award Issues Related to Human Research and Animal Use March 15, 2013.
OVERVIEW OF DACA BIOEQUIVALENCE REPORT EVALUATION Presented by Solomon Shiferaw 31Augst 2010.
Local Public Health System Assessment using the NPHPSP Local Instrument Essential Service 6 Enforce Laws and Regulations that Protect Health and Ensure.
SFDA-2007 الهيئة العامة للغذاء والدواء Bioequivalence Studies of Generic Pharmaceutical Products Workshop-Day II Introduction and workshop Objectives By:
We have reviewed this material in accordance with U.S. Copyright Law and have tried to maximize your ability to use, share, and adapt it. The citation.
1 Health Exchange Proposal Delaware Health Care Commission May 5, 2011.
WHO Workshop on Assessment of Bioequivalence Data Addis Ababa, 31. August – 3. September Frequent Deficiencies Dr. Henrike Potthast
Accreditation in the higher education
ACCESS TO MEDICINES - POLICY AND ISSUES
Lucile de Comarmond Chief Pharmacist Workshop on Impact of TRIPS/IP on Access to Medicine September 2014.
Quality of Bioequivalence Data Alfredo García - Arieta Training workshop: Training of BE assessors, Kiev, October 2009.
ASPECTS AFFECTING THE HOSPITAL OPERATION Financial Financial Operational Operational Administrative Administrative Clinical Clinical Safety Safety.
Office of Research & Development (ORD) Local Accountability of Research 2009 Baltimore, Maryland January 13-14, 2009 “Meeting the Current Challenges of.
Organization and Implementation of a National Regulatory Program for the Control of Radiation Sources Regulatory Authority.
“The Quality Infrastructure in Lebanon” Export Norms, Quality Control and Competitiveness FUTURE PROGRAMME Prepared By Ali Berro Director of Quality Programme.
UNECE – SIDA “ SOUTH EAST EUROPE REGULATORY PROJECT” FIRST MEETING OF REGULATORS FROM SOUTH EAST EUROPEAN COUNTRIES PRESENTATIONFROM THE REPUBLIC OF MACEDONIA.
Training Workshop: Training of BE Assessors Kiev, October 2009 Frequent Deficiencies Dr. Henrike Potthast Training workshop: Training.
Slide 1 of 10D.K. Mubangizi, Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community.
Staffing and training. Objectives To understand approaches to the development of strategies and policies for staffing of a Regulatory Authority including.
WHO FOOD LAW COURSE UK EXPERIENCE OF FOOD LAW DEVELOPMENT AND ENFORCEMENT.
Organization and Implementation of a National Regulatory Program for the Control of Radiation Sources Technical Services.
1 QUALITY MANAGEMENT SYSTEM PRESENTATION TO BOTSWANA DRUG ADVISORY BOARD MEMBERS 13 th – 17 th AUGUST 2007.
1 CHALLENGES IN REGULATING QUALITY AND RATIONAL USE OF ANTIBIOTICS ALLIANCE FOR THE PRUDENT USE OF ANTIBIOTICS: INAGURAL MEETING COURTYARD.
Korea Food & Drug Administration Deputy director Kwang-Soo Joo Korea FDA Sep. 29, 2000 : Korean Good Clinical Practice & Relative Guidelines How to Manage.
The First Conference for Medicines Regulatory Authorities In Sudan and Neighboring Countries Khartoum December 2014 Alain PRAT, Technical Officer,
Prepared by: Imon Rahman Lecturer Department of Pharmacy BRAC University.
Good Laboratory Practice - general information Pirkko Puranen Senior Inspector, Ph.D. Inspectorate.
Quality Metrics of Performance of Research Ethics Committees Cristina E. Torres, PhD FERCAP Coordinator.
GCP (GOOD CLINICAL PRACTISE)
INTRODUCTION A national drug policy is a document which covers all the areas and issues related to drugs. This document outlines all aspects of drugs.
Technical Services. Objectives To identify the technical services needed within the infrastructure for an effective implementation of regulatory programme.
Responsibilities of Sponsor, Investigator and Monitor
Responsibilities of Sponsor, Investigator and Monitor
EAST AFRICAN COMMUNITY MEDICINES REGULATORY HARMONIZATION (EAC-MRH) PROJECT PROGRESS NAIROB I - KENYA By: EAC - Secretariat.
ICH-GCP Avinash Kondawar M. Pharm Lead CRA
LNH Pharma A Trusted Partner.
External Validation of Quality Programs
Clinical Engineering Lecture (3).
Lesson 5: BRITE Seminar: GMP II
Standardization in the Beauty and Wellness Sector
Good Laboratory Practices
Chemical Purchasing.
ISO 9000 Dr. S. Thomas Foster, Jr..
External Validation of Quality Programs
OSU Controlled Substances Training Module for Researchers
Presentation transcript:

1 Current Issues for Conduction of BE Studies in Pakistan 1 st Symposium on Bioequivalence and Bioavailability Studies April 2014, Lahore, Pakistan Dr. Zeba Ahmed Shuja TECHNICAL DIRECTOR SCHAZOO ZAKA Pvt. Ltd. Lahore, Pakistan

BE Studies Current Issues 1. BE Study Regulatory issues 2. Selection and arrangement of comparator product and Reference Standard 3. BE Study Volunteers issues 4. BE Study Organizational issues 5. BE Study Costing issues 6. Ethics Committee issues 2

3 1. Currently BE Studies rule not enforced at the time of registration of Generic Drugs by Drug Regulatory Authority Pakistan, MOH 2. No procedure in place for Contract Research Organizations Public/Private inspection and approvals 3. Similarly currently BE study Protocols not being approved by MOH. BE Study Regulatory Issues

4 4. According to the drug act 1976, Section 11 point 5(g) page 37 Provincial Quality Control Board: The following shall be the powers of the Provincial Quality Control Board…… g) Identify and accredit on payment of fee other laboratories in the province with suitable facilities and expertise BE Study Regulatory Issues ….

5. Health Department Punjab has adopted BE studies as compulsory for Bid evaluation for the procurement of drugs/medicines for the financial year ? A, Center for BE Studies and Bioassay Research Institute University of Karachi B, University of Veterinary Animal Sciences Lahore C, Dow University of Medical & Health Sciences Karachi D, Faculty of Pharmacy Islamia University Bahawalpur 5

6 1. WHO recommended comparator product should be used to conduct BE study from ICH countries (EU, Japan, UK) 2. On line pharmacies not reliable: delivery and storage condition problems 3. Government support needed in duty free custom clearance. Selection and Arrangement of Comparator Product

7 Arrangement of Reference Standard 1.An authenticated analytical reference standard of known identity and purity should be purchased either from USP, WHO & EP or from well reputable source like Sigma etc. should be used to prepare solutions of known concentrations

8 BE Study Volunteers Issues 1. There is no proper system of volunteers insurance. 2. Difficult to arrange healthy volunteers for initial screening. Women do not volunteer in Pakistan. Generally 24 volunteers are essential for any single cross over study according to WHO guidelines. Studies using volunteers are also conducted.

BE Study Volunteers Issues…. 3. Difficulties in blood sampling due to lack of trained stuff resulting in blockage of cannula during blood sampling causing Direct sampling, Less volume sampling & Haemolysis, leading to Volunteer discomfort Problem related to volunteers next follow up visit, Time punctuality & no show problems 4. Problem related to volunteers next follow up visit, Time punctuality & no show problems 4.. 9

10 BE Study Organizational Issues 1. Lack of proper standard operating procedures i.e., weak documentation in case of deviation from Protocol. 2. Lack of resource like skilled Phlebotomists / Analysts, calibrated and qualified analytical instruments i.e., HPLC/LCMS instrument 3. Non availability of validated bio-analytical methods. No studies done on the stability of the analyte in the plasma indifferent storage conditions

BE Study Organizational Issues…. 4. BE center’s do not meet the international WHO current Good Laboratory Practices, and Good Clinical Practices requirements 5. No timeline commitment for bioanalytical method development, bioanalytical method validation, protocol preparation, study execution and report preparation in the Centers 11

BE Study Organizational Issues…. 6. Insufficient stock of Chemicals, analytical columns and guard columns etc. 7. Documents eg. like Case Report Form not filled and signed on time 8. No Quality Assurance System established or followed properly. 12

13 Estimated cost / BE study in Pakistan is Approx. 20,000 US $. Internationally up to 100,000 US $ 1.Cost of documentation i.e., bio protocol preparation, review and aproval. Report preparation about pages 2.Cost of subject’s recruitment, complete blood and urine testing, ECG, X-RAY, subject’s insurance, follow up and confinement and catering etc. BE Study Cost Issues

BE Study Cost Issues …. 3. No Tax relaxation on the purchase of comparator product from ICH countries Reference Standard from USP/EP, Statistical Experts Cost. 4. Cost of blood collection tubes (cryo tubes), Cost of processing and storage, cost of support staff (phlebotomist, doctor, pharmacist and biochemist etc.) 5. Maintenance of sensitive analytical instruments like LCMS, HPLC ( Chemicals, columns) 14

Ethics Committee Issues…. 1.Should have 5 Members at least. With prime responsibility to verify safety, integrity & human rights of volunteers 2.One Independent Member not linked to the Center and one Physician required. 3.One Community nonscientific member 4.Only independent members should vote on a trial related matter 15

Recommendations : Laws 1.Proper Law under Federal DRAP by consensus of all stake holders Should make guidelines based on Int. Standards to Conduct, Inspect and Approve all Centers for performing BE studies. 2.System of getting BE Protocol approved in fast track before start of any study for a minor fee. 3.Duty free and fast track purchase to be allowed of Comparator Product from ICH countries & Reference Standard from EP /USP. 16

Recommendations : Laws 1.Encourage Centers to get ISO certification so that a minimum quality standard of testing is maintained. Financial subsidy or refund of cost? 2.Encourage The Pharma Industry by giving a reasonable timeline of 3-5 years for Compliance to registration of Generic Drugs with authentic BE Studies or Biowaver Dissolution Studies. Similar criteria to be followed for registered Antibiotics and Life saving drugs. 3.System of getting BE Protocol approved in fast track before start of any study for a minor fee. 4.Duty free and fast track purchase to be allowed of Comparator Product from ICH countries & Reference Standard from EP /USP. 17

Recommendations : BE Centers 1.Staff ( Phlebotomists, Doctors, Analysts) should be continuously trained to follow international standards for conduction and reporting of BE Studies. Co-operation among Centers. 2. Adequate Number of Qualified staff must be employed & Volunteer rights must be ensured by proper Insurance. 3.Ethics Committee Structure must be as per International Standards with actual powers. 18

Recommendations : Pharmaceutical Industry 1.High time the Pharmaceutical Industry realizes the ethical and moral responsibility of conducting BE studies to ensure Efficacy, safety and Quality of Generic Drug Products in Pakistan. 2.Financial benefits of Opening doors for export of Generic Drugs to ICH countries with highest expenditure on Health Care. 3.All stakeholders must co-operate with each other to achieve any success. 19

20 Thank You